Risks

While false positive screening tests have the potential to result in further testing, radiation exposure, cost and possibly unnecessary biopsy or surgeries which entail additional risks.  These potential problems can be safely managed with adherence to a well-developed protocol for the screening, diagnosis and treatment of early lung cancer.  Pooling the findings of the NLST, I-ELCAP and other international studies can translate the acquired data into a protocol that will provide patients the maximum benefits from screening with the lowest possible risks.